Association of Plasminogen Activator Inhibitor-Type 1 (-675 4G/5G) Polymorphism with Pre-Eclampsia: Systematic Review

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Morgan, Jessie A ^a   Bombell, Sarah ^b   McGuire, William ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Goulburn Base Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; ECLAMPSIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HELLP SYNDROME; HUMAN; MATERNAL HYPERTENSION; PATHOGENESIS; PREECLAMPSIA; RISK FACTOR; SYSTEMATIC REVIEW;

FEMALE; GENOTYPE; HUMANS; MODELS, GENETIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY;

EID: 84874052261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056907     Document Type: Article

References (62)

1. Roberts JM, Cooper DW, (2001) Pathogenesis and genetics of pre-eclampsia. Lancet 357: 53-6.
2. Williams PJ, Broughton Pipkin F, (2011) The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 25: 405-17.
3. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, et al. (2001) Association of maternal endothelial dysfunction with preeclampsia. JAMA 285: 1607-12.
4. Belo L, Santos-Silva A, Rumley A, Lowe G, Pereira-Leite L, et al. (2002) Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. BJOG 109: 1250-5.
5. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR, (1989) Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 74: 1332-8.
6. Koh SC, Anandakumar C, Montan S, Ratnam SS, (1993) Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. Gynecol Obstet Invest 35: 214-21.
7. Roes EM, Sweep CG, Thomas CM, Zusterzeel PL, Geurts-Moespot A, et al. (2002) Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Am J Obstet Gynecol 187: 1019-25.
8. Clausen T, Djurovic S, Reseland JE, Berg K, Drevon CA, et al. (2002) Altered plasma concentrations of leptin, transforming growth factor-beta(1) and plasminogen activator inhibitor type 2 at 18 weeks of gestation in women destined to develop pre-eclampsia. Circulating markers of disturbed placentation? Placenta 23: 380-5.
9. Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, et al. (2005) Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 112: 1129-37.
10. Huang J, Sabater-Lleal M, Asselbergs FW, Tregouet D, Shin SY, et al. (2012) Genome-wide association study for circulating levels of plasminogen activator inhibitor-1 (PAI-1) provides novel insights into the regulation of PAI-1. Blood Sep 18 [Epub ahead of print].
11. D'Elia AV, Fabbro D, Driul L, Barillari G, Marchesoni D, et al. (2011) Plasminogen activator Inhibitor-1 gene polymorphisms in pre-eclampsia. Semin Thromb Hemost 37: 97-105.
12. Wiwanitkit V, (2006) Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal. Arch Gynecol Obstet 273: 322-4.
13. Serrano NC, Díaz LA, Páez MC, Mesa CM, Cifuentes R, et al. (2006) Angiotensin-converting enzyme I/D polymorphism and preeclampsia risk: evidence of small-study bias. PLoS Med 3(12): e520.
14. Shaik AP, Sultana A, Bammidi VK, Sampathirao K, Jamil K, (2011) A meta-analysis of eNOS and ACE gene polymorphisms and risk of pre-eclampsia in women. J Obstet Gynaecol 31: 603-7.
15. Sagoo GS, Little J, Higgins JPT, (2009) Systematic Reviews of Genetic Association Studies. PLoS Med 6(3): e1000028.
16. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, et al. (1997) Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 157: 715-25.
17. Rodriguez S, Gaunt TR, Day IN, (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169: 505-514.
18. Higgins JPT, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-58.
19. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34.
20. Altman DG, Bland JM, (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
21. Cole P, MacMahon B, (1971) Attributable risk percent in case-control studies. Br J Prev Soc Med 25: 242-4.
22. Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, et al. (2000) The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 45: 138-41.
23. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, et al. (2002) Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 87: 779-85.
24. Pegoraro RJ, Hira B, Rom L, Moodley J, (2003) Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia. Acta Obstet Gynecol Scand 82: 313-7.
25. Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, et al. (2003) Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 7: 265-8.
26. Fabbro D, D'Elia AV, Spizzo R, Driul L, Barillari G, et al. (2003) Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 56: 17-22.
27. Tempfer CB, Jirecek S, Riener EK, Zeisler H, Denschlag D, et al. (2004) Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. J Soc Gynecol Investig 11: 227-31.
28. De Maat MP, Jansen MW, Hille ET, Vos HL, Bloemenkamp KW, et al. (2004) Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2: 1588-93.
29. Gerhardt A, Goecke TW, Beckmann MW, Wagner KJ, Tutschek B, et al. (2005) The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost 3: 686-91.
30. Dalmáz CA, Santos KG, Botton MR, Tedoldi CL, Roisenberg I, (2006) Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population. Blood Cells Mol Dis 37: 107-10.
31. Muetze S, Eggermann T, Leeners B, Birke C, Kuse S, et al. (2007) The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome. J Thromb Thrombolysis 27: 141-5.
32. Kobashi G, Ohta K, Yamada H, Hata A, Minakami H, et al. (2009) 4G/5G variant of plasminogen activator inhibitor-1 gene and severe pregnancy-induced hypertension: subgroup analyses of variants of angiotensinogen and endothelial nitric oxide synthase. J Epidemiol 19: 275-280.
33. Said JM, Tsui R, Borg AJ, Higgins JR, Moses EK, et al. (2012) The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women. J Thromb Haemost 10: 881-886.
34. Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, et al. (2000) The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 49: 845-52.
35. Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, et al. (2001) Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 97: 44-8.
36. Larciprete G, Gioia S, Angelucci PA, Brosio F, Barbati G, et al. (2007) Single inherited thrombophilias and adverse pregnancy outcomes. J Obset Gynecol 33: 423-430.
37. Bertolino OW, Labate F, Bertolino EC, Rannazzisi M, Assadi G, et al. (2009) Trombofilia ereditaria e complicanze gravidiche nella popolazione siciliana. It J Gynaec Obstet 21: 129-36.
38. Guan LX, Du XY, Wang JX, Wang RL, Wu ZL, et al. (2004) Relationship between the 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and the pathogenesis of pregnancy-induced hypertension syndrome. Zhonghua Yi Xue Chuan Xue Za Zhi 2: 173-5.
39. D'Aniello G, Florio P, Sabatini L, Severi FM, Fineschi D, et al. (2003) The search for thrombophilic gene mutation in women with gestational hypertension does not help in predicting poor pregnancy outcomes. J Hypertens 21: 1915-20.
40. Kobashi G. Genetic and environmental factors associated with the development of hypertension in pregnancy. J Epidemiol 2006: 1-8.
41. Mozgovaia EV, Malysheva OV, Ivashchenko TE, Branov VS, (2002) Genetic predisposition to pre-eclampsia: Polymorphism of genes involved in regulation of endothelial functions. Balkan J Med Genetics 5: 19-26.
42. Kamal M, El-Khayat W, (2011) Do serum angiopoietin-1, angiopoietin-2, and their receptor Tie-2 and 4G/5G variant of PAI-1 gene have a role in the pathogenesis of preeclampsia? J Investig Med 59: 1147-50.
43. Abdelaziz NA, Abu Saif AH, (2008) Alshishtawy (2008) Relationship between polymorphism in thrombophilic genes and preeclampsia in Egyptian population. Egypt J Hosp Med 33: 503-9.
44. Koleva R, Dimitrova V, Chernev T, Savov A, Karag'ozova Zh, et al. (2005) Impact of inherited thrombophilia on the development of some pregnancy complications. Akush Ginekol (Sofia) 44: 18-26.
45. Ivanov P, Komsa-Penkova R, Ivanov I, Bozhinova S, Stoianova A, (2007) Carriers of thrombophilic factor among women with preeclampsia (preliminary report). Akush Ginekol (Sofia) 46: 3-14825.
46. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G, (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27: 1133-63.
47. Gohil R, Peck G, Sharma P, (2009) The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 102: 360-70.
48. Kosmas IP, Tatsioni A, Ioannidis JP, (2004) Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 22: 1655-62.
49. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, et al. (2006) Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10: 1-110.
50. Ioannidis JP, Ntzani EE, Trikalinos TA, (2001) Replication validity of genetic association studies. Nat Genet 29: 306-9.
51. Salanti G, Sanderson S, Higgins J, (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7: 13-20.
52. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG, (2003) Genetic associations in large versus small studies: An empirical assessment. Lancet 361: 567-571.
53. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP, (2005) Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Medicine 2: e334.
54. Kosmas IP, Tatsioni A, Ioannidis JP, (2003) Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 21: 1221-8.
55. Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, et al. (2008) Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 6: 1869-75.
56. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, et al. (2010) The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 15 7(6): e1000292.
57. Hattersley AT, McCarthy MI, (2005) What makes a good genetic association study? The Lancet 366: 1315-23.
58. Caughey AB, Stotland NE, Washington AE, Escobar GJ, (2005) Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol 106: 156-61.
59. GOPEC Consortium, (2005) Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet 77: 127-31.
60. Goddard KA, Tromp G, Romero R, Olson JM, Lu Q, et al. (2007) Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered 63: 1-16.
61. Yesupriya A, Evangelou E, Kavvoura FK, Patsopoulos NA, Clyne M, et al. (2008) Reporting of human genome epidemiology (HuGE) association studies: an empirical assessment. BMC Med Res Methodol 8: 31.
62. Salanti G, Amountza G, Ntzani EE, Ioannidis JP, (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 13: 840-8.